- $13.99m
- -$9.75m
- $65.30m
- 46
- 45
- 42
- 40
Annual balance sheet for MEI Pharma, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K/A | 10-K/A | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 183 | 153 | 153 | 101 | 38.3 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 23.3 | 7.58 | 10 | 0.085 | 0 |
| Prepaid Expenses | |||||
| Total Current Assets | 209 | 165 | 167 | 108 | 40.8 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 1.08 | 9.28 | 10.7 | 13.3 | 0.606 |
| Total Assets | 210 | 174 | 178 | 121 | 41.4 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 13.8 | 20.2 | 24.4 | 20.3 | 8.36 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 133 | 125 | 125 | 96.2 | 8.36 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 77.1 | 49.5 | 52.4 | 24.6 | 33 |
| Total Liabilities & Shareholders' Equity | 210 | 174 | 178 | 121 | 41.4 |
| Total Common Shares Outstanding |